Synlogic (NASDAQ:SYBX) has earned an average recommendation of “Hold” from the six analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.00.
A number of analysts have recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Synlogic in a report on Tuesday. Zacks Investment Research raised shares of Synlogic from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Piper Jaffray reaffirmed a “buy” rating and set a $15.00 price target on shares of Synlogic in a report on Monday, April 9th. Finally, ValuEngine cut shares of Synlogic from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd.
Several large investors have recently modified their holdings of SYBX. Artal Group S.A. bought a new position in shares of Synlogic in the 4th quarter worth approximately $5,335,000. Spark Investment Management LLC bought a new position in shares of Synlogic in the 4th quarter worth approximately $105,000. Renaissance Technologies LLC bought a new position in shares of Synlogic in the 4th quarter worth approximately $191,000. Finally, Deutsche Bank AG lifted its stake in shares of Synlogic by 204.0% in the 4th quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock worth $190,000 after purchasing an additional 13,200 shares during the period. Hedge funds and other institutional investors own 55.53% of the company’s stock.
Shares of NASDAQ SYBX opened at $11.38 on Friday. The company has a current ratio of 9.82, a quick ratio of 9.82 and a debt-to-equity ratio of 0.01. The stock has a market cap of $224.07, a PE ratio of -1.94 and a beta of 2.21. Synlogic has a 52-week low of $8.76 and a 52-week high of $23.00.
Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Tuesday, March 20th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.07. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.11 million. equities research analysts forecast that Synlogic will post -2.98 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Synlogic (SYBX) Receives $20.00 Average PT from Brokerages” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/17/synlogic-sybx-receives-20-00-average-pt-from-brokerages.html.
Synlogic Company Profile
Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.